Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

A recent report from Stifel showed that 30% of licensing deals from big pharma companies now involve a Chinese biotech.

Background: Lung cancer possesses the highest incidence and mortality rates ... we have initially identified and introduced a series of research hotspots and emerging frontiers, including “biomarkers” ...

Inhibitors of programmed cell death protein 1 and its associated ligand (PD-L1) are widely used in cancer treatment ... authors, and research hot spots. Moreover, substantial differences between ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...